Practice Pearls for Physicians Considering CAR T-cell Therapy for Patients with LBCL
February 2nd 2023Closing out this discussion of post-ASH 2022 perspectives, Matthew Lunning, DO, FACP, shares important clinical practice pearls for physicians considering CAR T-cell therapy for patients with LBCL.
Read More
Choosing the Appropriate CAR T-Cell Therapy in Patients with R/R DLBCL
February 2nd 2023Dr Lunning, DO, FACP, shares his impressions on the toxicity profile of axi-cel and liso-cel, and how he approaches treatment decision making for patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).
Read More
Clinical Trials Evaluating CAR T-Cell Therapies in Second-Line Treatment of Patients With DLBCL
July 28th 2022Frederick Locke, MD, provides an in-depth look at data from 3 clinical trials investigating chimeric antigen receptor T-cell therapy in the second-line treatment of diffuse large B-cell lymphoma.
Read More